Overview |
bs-11649R-FITC |
ALS2CR1/NIF3L1 Polyclonal Antibody, FITC Conjugated |
WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human, Mouse, Rat, Dog, Cow, Rabbit |
Specifications |
FITC |
Rabbit |
KLH conjugated synthetic peptide derived from human ALS2CR1/NIF3L1 |
201-300/377 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
Cytoplasm |
ALS2CR1; Amyotrophic lateral sclerosis 2 juvenile chromosome region, candidate 1; Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 1 protein; CALS-7; MDS015; Ngg1 interacting factor 3-like 1; N3 Ngg1 interacting factor 3, S.pombe homolog-like 1; N3 NGG1 interacting factor 3-like 1 S. pombe; N3 NGG1 interacting factor 3-like 1; N3-like protein 1; N3L_HUMAN; N3L1. |
The NGG1 interacting factor 3-like 1 (NIF3L1) is a 377 amino acid protein expressed mainly in the cytoplasm of cells in several different tissues. It has been highly conserved throughout evolution, from bacteria to mammals. NIF3L participates in retinoic acid-primed neural differentiation of P19 embryonic carcinoma cells by cooperating with Trip15/CSN2, a transcriptional corepressor/component of COP9 signalosome. NIF3L1 interacts with itself and with the NIF3L1 binding protein 1 (NIF3L1 BP1), which is a novel protein presumed to contain a leucine zipper domain. |
Application Dilution |
WB |
1:300-5000 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |